Taysha Gene Therapies, Inc. TSHA R2K

Healthcare · Biotechnology · United States

https://www.tayshagtx.com

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Market & Price

Market Cap

$1.69B

Current Price

$5.87

High / Low (52W)

$6.98 / $2.31

Beta

1.23

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$0.87

Price to Book

6.78

P/S

225.78

EV/EBITDA

-11.25

Dividend Yield

Profitability & Returns

ROCE

-34.39%

ROE

-97.28%

ROA

-37.77%

Profit Margin

0.00%

Op Margin

EPS (Latest Qtr)

$-0.12

EPS (TTM)

$-0.38

Balance Sheet & Liquidity

Debt/Equity

0.32

Quick Ratio

13.76

Current Ratio

14.04

Debt

$68.55M

Total Assets

$343.32M

Current Assets

$324.65M

Working Capital

$298.10M

Ownership

Promoter Holding

10.62%

Chg in Prom Hold

FII / Inst Holding

95.74%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.48B

Total Revenue (TTM)

$7.47M

EBITDA

$-131.41M

Free Cash Flow

$-73.45M

Operating Cash Flow

$-111.95M

Shares Outstanding

287.36M

Gross Margin

100.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

57.49%

Profit 5Y

11.45%

Revenue (YoY)

Earnings (YoY)

PROS

Compounding revenue at 57.5% over 5 years.
Profit CAGR of 11.4% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TSHA Taysha Gene Therapies, Inc. R2K	5.87	-	$1.69B	-	-34.39%	-97.28%	57.49%	11.45%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	4.71M	2.40M	4.75M	3.41M	1.11M	-	-	2.30M	1.99M	0	5.49M	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23.72M	28.74M	34.02M	33.78M	43.49M
Operating Income	-1.11M	-5.58M	-4.01M	-15.04M	-32.09M	-40.77M	-50.68M	-49.65M	-33.37M	-25.46M	-16.56M	-23.38M	-16.25M	-24.33M	-21.30M	-	-	-21.42M	-26.75M	-34.02M	-28.30M	-43.49M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.23M	-26.59M	-32.43M	-27.54M	-42.11M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.00K	17.00K	15.00K	12.00K	9.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.53M	-26.88M	-32.73M	-27.85M	-42.41M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.11M	-5.43M	-21.22M	-15.04M	-32.02M	-40.93M	-51.19M	-50.32M	-34.09M	-26.53M	-17.62M	-24.60M	-117.09M	-24.06M	-20.93M	-	-	-21.53M	-26.88M	-32.73M	-27.85M	-42.41M
Diluted EPS	-	-	-	-	-	-1.09	-1.35	-1.32	-0.85	-0.65	-0.28	-0.38	-0.93	-0.10	-0.09	-0.10	-	-0.08	-0.09	-0.09	-	-0.12
R&D Expense	987.00K	5.51M	3.06M	11.06M	23.85M	30.64M	39.53M	38.18M	23.51M	16.77M	12.51M	19.79M	11.79M	20.66M	15.07M	14.95M	-	15.56M	20.14M	25.75M	-	33.81M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	2.50M	15.45M	8.33M	9.77M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	-	-	128.53M	86.83M	94.95M	120.27M
Operating Income	-43.00M	-	-126.03M	-71.37M	-86.62M	-110.50M
EBITDA	-	-	-161.04M	-105.20M	-87.95M	-107.79M
Interest Expense	-	-	3.80M	5.00M	102.00K	63.00K
Pretax Income	-	-	-166.01M	-111.57M	-89.30M	-109.00M
Tax Provision	-	-	-	-	-	-
Net Income	-60.01M	-	-166.01M	-111.57M	-89.30M	-109.00M
Diluted EPS	-	-4.64	-3.78	-0.96	-0.36	-
R&D Expense	31.89M	131.94M	91.17M	56.78M	66.00M	86.40M

Compounded Sales Growth

5 Years:	57.49%
1 Year:	-

Compounded Profit Growth

5 Years:	11.45%
1 Year:	-

Stock Price Performance

1 Year:	+116.61%
6 Months:	+27.89%
3 Months:	+29.58%
1 Month:	-6.38%

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2019	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	15.00K	258.88M	-	126.28M	172.73M	160.36M	343.32M
Current Assets	-	-	-	-	96.42M	149.87M	142.13M	324.65M
Cash & Equivalents	-	-	251.25M	-	87.88M	143.94M	139.04M	319.77M
Inventory	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-
Total Liabilities	-	150.00K	7.58M	-	125.33M	97.79M	88.84M	96.38M
Current Liabilities	-	150.00K	7.13M	-	62.79M	36.76M	26.23M	26.55M
Long Term Debt	-	-	-	-	37.97M	40.51M	43.94M	50.11M
Total Debt	-	-	-	-	59.93M	61.11M	63.18M	70.14M
Total Equity	0	-135.00K	251.30M	-	949.00K	74.94M	71.53M	246.94M
Shares Outstanding	-	-	-	-	63.21M	186.96M	204.94M	285.05M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-30.73M	-	-88.39M	-73.02M	-81.22M	-93.09M
Investing Cash Flow	-9.08M	-	-24.93M	-7.35M	-363.00K	-604.00K
Financing Cash Flow	291.06M	-	52.10M	136.39M	76.68M	274.59M
Capital Expenditure	-82.00K	-	-24.87M	-7.37M	-374.00K	-738.00K
Free Cash Flow	-30.81M	-	-113.26M	-80.39M	-81.60M	-93.83M
Net Change in Cash	-	-	-61.22M	56.02M	-4.90M	180.90M

Ratios (Annual)

Figures in %.

Metric	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-
Operating Margin %	-	-	-5,037.1%	-461.9%	-1,039.5%	-1,130.6%
Net Margin %	-	-	-6,635.3%	-722.1%	-1,071.6%	-1,115.3%
ROE %	-23.9%	-	-17,493.6%	-148.9%	-124.8%	-44.1%
ROCE %	-17.1%	-	-198.5%	-52.5%	-64.6%	-34.9%

Shareholding Pattern

Insiders

10.62%

Institutions

95.74%

Public Float

107.11%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	RA Capital Management, L.P.	8.20%	23.56M	$138.27M
2	Goldman Sachs Group Inc	7.78%	22.37M	$131.31M
3	Avoro Capital Advisors LLC	7.55%	21.70M	$127.38M
4	Blackrock Inc.	6.39%	18.37M	$107.81M
5	Vestal Point Capital, LP	6.26%	18.00M	$105.66M
6	Morgan Stanley	6.25%	17.97M	$105.46M
7	FMR, LLC	4.98%	14.32M	$84.07M
8	RTW Investments LP	4.76%	13.68M	$80.30M
9	State Street Corporation	3.90%	11.21M	$65.80M
10	Vanguard Capital Management LLC	3.56%	10.23M	$60.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TSHA

No recent headlines available.

TSHA · Healthcare